Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
News|Articles|June 24, 2025 (Updated: June 26, 2025)
Q3 2025: 10 FDA Decisions to Watch in the Realm of Oncology
Author(s)OncLive Staff
Fact checked by: Kristi Rosa
Here is your Q3 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for sunvozertinib, linvoseltamab, vuslimogene oderparepvec, and more.
Advertisement
Advertisement
As the second quarter of 2025 closes, the pace of oncology innovation shows no signs of slowing. Recent FDA approvals have reinforced the shift toward more targeted, immunologically driven, and personalized therapies across a broad spectrum of cancers.
Related to this article
Five Huntsman Cancer Institute at the University of Utah colleagues earned endowed chair appointments, including new appointments.
The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
Advertisement
Advertisement